Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648555 | 1.00 | KDM4E (0.47) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14406177 | 0.92 | KDM4E (0.43) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL438497 | 0.86 | MEN1 (0.38) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL105227 | 0.86 | KEAP1 (0.54) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL441441 | 0.85 | KEAP1 (0.52) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL28575023 | 0.84 | LMNA (0.46) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25299334 | 0.84 | USP2 (0.52) | KDM4EALDH1A1SMN1; SMN2KEAP1USP2 | |
| SCHEMBL1453895 | 0.84 | USP2 (0.52) | KDM4EALDH1A1SMN1; SMN2KEAP1USP2 | |
| SCHEMBL8428226 | 0.84 | MEN1 (0.39) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8106724 | 0.83 | SMN1; SMN2 (0.50) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1024 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1073553-C | Process for producing N-arylhydroxylamines and N-hetarylhydroxylamines | BASF AG (DE) | 2001-10-24 | — | — | CN | claimed |
| US-6031106-A | Process and intermediate products for preparing pyridyl-4-fluoroanilines | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | claimed |
| EP-0805797-B1 | PROCESS FOR PRODUCING N-ARYLHYDROXYLAMINES AND N-HETARYLHYDROXYLAMINES | BASF AG (DE) | 1999-04-07 | — | — | EP | claimed |
| US-5831093-A | CATALYTIC HYDROGENATION OF NITRO COMPOUNDS | BASF AKTIENGESESCHAFT (DE) | 1998-11-03 | — | — | US | claimed |
| CN-1169715-A | Process for producing N-arylhydroxylamines and N-hetarylhydroxylamines | BASF AG (DE) | 1998-01-07 | — | — | CN | claimed |
| EP-0805797-A1 | PROCESS FOR PRODUCING N-ARYLHYDROXYLAMINES AND N-HETARYLHYDROXYLAMINES | BASF AKTIENGESELLSCHAFT (DE) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022967-A1 | PROCESS FOR PRODUCING N-ARYLHYDROXYLAMINES AND N-HETARYLHYDROXYLAMINES | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-01 | — | — | WO | claimed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | SHEWCHUK LISA M | 2007-01-11 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| CN-1073553-C | Process for producing N-arylhydroxylamines and N-hetarylhydroxylamines | BASF AG (DE) | 2001-10-24 | — | — | CN | disclosed |
| EP-0805797-B1 | PROCESS FOR PRODUCING N-ARYLHYDROXYLAMINES AND N-HETARYLHYDROXYLAMINES | BASF AG (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-5831093-A | CATALYTIC HYDROGENATION OF NITRO COMPOUNDS | BASF AKTIENGESESCHAFT (DE) | 1998-11-03 | — | — | US | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| CN-1169715-A | Process for producing N-arylhydroxylamines and N-hetarylhydroxylamines | BASF AG (DE) | 1998-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | KDM4E 3505/4885MEN1 4422/4885KMT2A 3421/4885 |
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | KDM4E 3888/4885MEN1 3081/4885KMT2A 4247/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | KDM4E 3521/4885MEN1 2456/4885KMT2A 3563/4885 |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | FAM20C, FRS2, FRK | KDM4E 4461/4885MEN1 1516/4885KMT2A 3069/4885 |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, ACAT2 | KDM4E 2897/4885MEN1 3340/4885KMT2A 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.